Invloed van de pH op het aantonen van bacteriegroeiremmende stoffen in rauwe melk

Een hoeveelheid melk wordt toegevoegd aan een vaste voedingsbodem, waaraan sporen van Bacillus stearothermophilus var. calidolactis ATCC 10149, broomcresolpurper en trimethoprim zijn toegevoegd. Normale groei van en zuurproduktie door het micro-organisme veroorzaakt een kleurverandering van de pH indicator van paars naar geel. De aanwezigheid in de melk van stoffen die remmend werken op de groei van het micro-organisme, hebben tot gevolg dat de kleur van de pH indicator paars blijft. Nagegaan is of verhoging van de pH van de vaste voedingsbodem deze screeningsmethode gevoeliger maakt voor het opsporen van bacterie groeiremmende stoffen welke een hogere activiteit vertonen in een basisch milieu

Resultaten ringonderzoek residuen van chlooramfenicol in ei

De resultaten van dit onderzoek naar Chlooramfenicol (CAP) in eieren worden in dit rapport beschreven

Human herpes virus 6 reactivation:important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT

Hematopoietic SCT (HSCT) is often complicated by viral reactivations. In this retrospective cohort study (January 2004-August 2008), predictors for human herpes virus 6 (HHV6)-reactivation and associations between HHV6-reactivation and clinical outcomes after allogeneic HSCT were studied. HHV6 DNA load in plasma was monitored weekly by quantitative real-time PCR. Associations between the main end point HHV6-reactivation and other end points, that is, acute GVHD (aGVHD) and NRM were analyzed using Cox proportional hazard models. In total, 108 patients receiving either a myeloablative (MA; n=60) or non-myeloablative (NMA; n=48) conditioning regimen were included. Median age was 40 years (range 17-65); median follow-up was 20 months (range 3-36). In 16/60 (27%) patients with MA conditioning regimen, a HHV6 reactivation was observed (mean viral load 50 323 cp/mL) compared with 2/48 (4%) patients with a NMA conditioning regimen with low viral load (mean 1100 cp/mL). In multivariate analysis, MA conditioning was the only predictor for HHV6 reactivation (P=0.02). In addition, HHV6 reactivation was associated with grades 2-4 aGVHD (P<0.001) and NRM (P=0.03). Regular monitoring of HHV6 reactivation after HSCT might be important in MA HSCT patients to enable early initiation of antiviral treatment or to anticipate aGVHD, all of which may improve clinical outcome

Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT

Hematopoietic SCT (HSCT) is often complicated by viral reactivations. In this retrospective cohort study (January 2004-August 2008), predictors for human herpes virus 6 (HHV6)-reactivation and associations between HHV6-reactivation and clinical outcomes after allogeneic HSCT were studied. HHV6 DNA load in plasma was monitored weekly by quantitative real-time PCR. Associations between the main end point HHV6-reactivation and other end points, that is, acute GVHD (aGVHD) and NRM were analyzed using Cox proportional hazard models. In total, 108 patients receiving either a myeloablative (MA; n = 60) or non-myeloablative (NMA; n = 48) conditioning regimen were included. Median age was 40 years (range 17-65); median follow-up was 20 months (range 3-36). In 16/60 (27%) patients with MA conditioning regimen, a HHV6 reactivation was observed (mean viral load 50 323 cp/mL) compared with 2/48 (4%) patients with a NMA conditioning regimen with low viral load (mean 1100 cp/mL). In multivariate analysis, MA conditioning was the only predictor for HHV6 reactivation (P = 0.02). In addition, HHV6 reactivation was associated with grades 2-4 aGVHD (P<0.001) and NRM (P = 0.03). Regular monitoring of HHV6 reactivation after HSCT might be important in MA HSCT patients to enable early initiation of antiviral treatment or to anticipate aGVHD, all of which may improve clinical outcome